NCT00755703View on ClinicalTrials.gov

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2011

Conditions

Influenza A Subtype H5N1 Infection

Interventions

BIOLOGICAL

Pandemic Influenza Vaccine

Undetermined

BIOLOGICAL

Placebo

Trial Locations (1)

35294-2050

Alabama Vaccine Research Center (UAB), Birmingham

Sponsors

Lead Sponsor

Altimmune, Inc.

All Listed Sponsors

lead

Altimmune, Inc.

INDUSTRY

NCT00755703 - Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. | Biotech Hunter | Biotech Hunter